Search - tctmd.com

Displaying 41 - 60 of 85

Sort: Relevancy | Date

Presentation TCT 2019

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Presenter: Usman Baber

September 26, 2019

Presentation TCT 2019

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

Presenter: Roxana Mehran

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

Presentation TCT 2018

HEALING-AMI: A Randomized Trial of Ticagrelor to Improve Left Ventricular Remodeling in ST-Segment Elevation Myocardial Infarction

Presenter: Dominick J. Angiolillo, Neal S. Kleiman, Yongwhi Park

September 24, 2018

Presentation TCT 2018

GLOBAL LEADERS: A Randomized Trial of Ticagrelor Monotherapy After PCI - Patient-Oriented Clinical Outcomes and Net Adverse Cardiovascular Events

Presenter: Dominick J. Angiolillo, Neal S. Kleiman, Patrick W. Serruys

September 24, 2018

Presentation TCT 2018

GLOBAL LEADERS in Perspective: Perspectives on Ticagrelor Monotherapy

Presenter: Dominick J. Angiolillo, Elmir Omerovic, Patrick W. Serruys

September 23, 2018

Presentation TCT 2018

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

Presenter: John A. Bittl, C. Michael Gibson, Dimitrios Alexopoulos

September 23, 2018

Polymer-Free BioFreedom Stent as Safe as Orsiro, but Not as Effective

News Conference News TCT 2018

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Michael O'Riordan

September 22, 2018

Presentation TCT 2017

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Presenter: John A. Bittl, Daniel I. Simon, C. Michael Gibson

October 30, 2016

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

Presentation TCT 2015

TCT 78: Efficacy of Long-term Ticagrelor in Stented Patients in PEGASUS-TIMI 54

Presenter: Lisa K. Jennings, Neal S. Kleiman, Marc Bonaca

October 13, 2015

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prehospital or Crushed Ticagrelor!

Presenter: Eric Boersma, E. Magnus Ohman, Dimitrios Alexopoulos

October 12, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Presenter: John A. Bittl, E. Magnus Ohman, Jorge F. Saucedo

October 11, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Presenter: John A. Bittl, E. Magnus Ohman, Christoph A. Kaiser

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman

October 11, 2015

Advertisement

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

HEALING-AMI: A Randomized Trial of Ticagrelor to Improve Left Ventricular Remodeling in ST-Segment Elevation Myocardial Infarction

GLOBAL LEADERS: A Randomized Trial of Ticagrelor Monotherapy After PCI - Patient-Oriented Clinical Outcomes and Net Adverse Cardiovascular Events

GLOBAL LEADERS in Perspective: Perspectives on Ticagrelor Monotherapy

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

TCT 78: Efficacy of Long-term Ticagrelor in Stented Patients in PEGASUS-TIMI 54

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prehospital or Crushed Ticagrelor!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content